Benchmark bolsters board

News
1885

Biotechnology business Benchmark has appointed non-executive directors with a combined 50 years of industry experience.

Hugo Wahnish has over 35 years of experience in the animal health and pharmaceuticals industry, including stints with GlaxoSmithKline and Merck during a period of major growth in the organisation.  

Wahnish held the post of Chief Commercial Officer Animal Health at Merck, having responsibility for Merck’s commercial operations worldwide.  Since stepping down from that role in 2012, he has acted as an independent senior advisor with several multinational companies, private equity groups and consulting firms primarily in the animal health sector.

Wahnish, based in the US, brings a wealth of international experience to the board of Benchmark, alongside his expertise in aggressively growing businesses and in the commercialisation of medicines and animal health products.

Nova Austral-chairman
Yngve Myhre has more than 20 years experience in the aquaculture sector as a senior executive, adviser and investor. 

Myhre was chief executive of leading Norwegian salmon producer Salmar, and of international white fish supplier Aker Seafood during periods of successful growth. He is now chairman of Chilean salmon producer Nova Austral, recently acquired by Altor and Bain, and sits on the boards of Mediterranean fish producer Andromeda and Norwegian aquaculture research institute Nofima. 

Myhre, who is based in Norway, also acts as strategic adviser to investors in the aquaculture sector. He has a very strong track record in Benchmark’s focus area of aquaculture, both in the Norwegian and international markets.